Aerovate Therapeutics's total assets for Q4 2024 were $80.33M, a decrease of -11.68% from the previous quarter. AVTE total liabilities were $3.90M for the fiscal quarter, a -62.76% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.